Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab + Ibrutinib followed by transplant or consolidation in pretreated high-risk CLL
2015-000684-13Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Jun 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab and ibrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by GIMEMA. Primary endpoint: Overall survival at 36 months. Started Jun 2021; status: completed.
02
Drugs
ofatumumabibrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2015-000684-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000684-13.